{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-038112","form_type":"8-K","ticker":"ANEB","cik":"0001815974","company_name":"Anebulo Pharmaceuticals, Inc.","filed_at":"2024-09-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.631771+00:00","generated_at":"2026-05-31T01:53:17.497691+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Anebulo Pharma reports Q4 FY2024 net loss $0.05/share; net loss down 48% YoY; awarded $1.9M NIDA grant","bullets":["Q4 FY2024 net loss $1.3M ($0.05/sh) vs $2.5M ($0.10/sh) in Q4 FY2023.","Full-year FY2024 net loss $8.2M ($0.32/sh) vs $11.7M ($0.47/sh) in FY2023.","Cash and equivalents $3.1M at June 30, 2024; additional $10M available under loan agreement.","Awarded up to $1.9M NIDA grant for IND-enabling activities for IV selonabant for pediatric cannabis poisoning.","Expects to enroll first healthy volunteer in H1 2025 for IV formulation clinical study."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-038112","json":"https://secwatch.observer/filing/0001493152-24-038112.json","markdown":"https://secwatch.observer/filing/0001493152-24-038112.md","text":"https://secwatch.observer/filing/0001493152-24-038112.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815974/000149315224038112/0001493152-24-038112-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815974/000149315224038112/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T01:53:17.497691+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}